S&P 500   4,370.95 (-1.62%)
DOW   34,473.52 (-1.14%)
QQQ   363.60 (-1.82%)
AAPL   144.19 (-0.81%)
MSFT   288.33 (-1.99%)
FB   343.50 (-2.85%)
GOOGL   2,741.40 (-2.84%)
TSLA   781.84 (-1.20%)
AMZN   3,335.44 (-2.07%)
NVDA   209.90 (-3.09%)
BABA   150.66 (+0.32%)
NIO   35.64 (-3.07%)
CGC   14.44 (-1.84%)
GE   105.03 (-0.30%)
MU   73.47 (-2.27%)
AMD   104.81 (-3.10%)
T   27.45 (+0.18%)
F   14.38 (+1.55%)
ACB   6.50 (+1.72%)
DIS   175.52 (-1.54%)
PFE   42.74 (-1.90%)
BA   220.77 (-1.51%)
AMC   37.61 (-4.30%)
S&P 500   4,370.95 (-1.62%)
DOW   34,473.52 (-1.14%)
QQQ   363.60 (-1.82%)
AAPL   144.19 (-0.81%)
MSFT   288.33 (-1.99%)
FB   343.50 (-2.85%)
GOOGL   2,741.40 (-2.84%)
TSLA   781.84 (-1.20%)
AMZN   3,335.44 (-2.07%)
NVDA   209.90 (-3.09%)
BABA   150.66 (+0.32%)
NIO   35.64 (-3.07%)
CGC   14.44 (-1.84%)
GE   105.03 (-0.30%)
MU   73.47 (-2.27%)
AMD   104.81 (-3.10%)
T   27.45 (+0.18%)
F   14.38 (+1.55%)
ACB   6.50 (+1.72%)
DIS   175.52 (-1.54%)
PFE   42.74 (-1.90%)
BA   220.77 (-1.51%)
AMC   37.61 (-4.30%)
S&P 500   4,370.95 (-1.62%)
DOW   34,473.52 (-1.14%)
QQQ   363.60 (-1.82%)
AAPL   144.19 (-0.81%)
MSFT   288.33 (-1.99%)
FB   343.50 (-2.85%)
GOOGL   2,741.40 (-2.84%)
TSLA   781.84 (-1.20%)
AMZN   3,335.44 (-2.07%)
NVDA   209.90 (-3.09%)
BABA   150.66 (+0.32%)
NIO   35.64 (-3.07%)
CGC   14.44 (-1.84%)
GE   105.03 (-0.30%)
MU   73.47 (-2.27%)
AMD   104.81 (-3.10%)
T   27.45 (+0.18%)
F   14.38 (+1.55%)
ACB   6.50 (+1.72%)
DIS   175.52 (-1.54%)
PFE   42.74 (-1.90%)
BA   220.77 (-1.51%)
AMC   37.61 (-4.30%)
S&P 500   4,370.95 (-1.62%)
DOW   34,473.52 (-1.14%)
QQQ   363.60 (-1.82%)
AAPL   144.19 (-0.81%)
MSFT   288.33 (-1.99%)
FB   343.50 (-2.85%)
GOOGL   2,741.40 (-2.84%)
TSLA   781.84 (-1.20%)
AMZN   3,335.44 (-2.07%)
NVDA   209.90 (-3.09%)
BABA   150.66 (+0.32%)
NIO   35.64 (-3.07%)
CGC   14.44 (-1.84%)
GE   105.03 (-0.30%)
MU   73.47 (-2.27%)
AMD   104.81 (-3.10%)
T   27.45 (+0.18%)
F   14.38 (+1.55%)
ACB   6.50 (+1.72%)
DIS   175.52 (-1.54%)
PFE   42.74 (-1.90%)
BA   220.77 (-1.51%)
AMC   37.61 (-4.30%)
ASX:BOT

Botanix Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.63 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive BOT News and Ratings via Email

Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.89 million
Book Value
A$0.02 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions

What stocks does MarketBeat like better than Botanix Pharmaceuticals?

Wall Street analysts have given Botanix Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Botanix Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Botanix Pharmaceuticals' earnings last quarter?

Botanix Pharmaceuticals Limited (ASX:BOT) announced its quarterly earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter.
View Botanix Pharmaceuticals' earnings history
.

Who are Botanix Pharmaceuticals' key executives?

Botanix Pharmaceuticals' management team includes the following people:
  • Mr. Vincent P. Ippolito, MD, Pres & Exec. Chairman (Age 62, Pay $808.16k)
  • Dr. Henry William Bosch, Chief Scientific Officer & Exec. Director
  • Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB, Exec. Director (Age 48, Pay $481.08k)
  • Dr. Clarence L. Young, Chief Medical Officer (Age 65)
  • Ms. Lynda Berne, Head of Commercial
  • Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA, Company Sec.

What other stocks do shareholders of Botanix Pharmaceuticals own?

What is Botanix Pharmaceuticals' stock symbol?

Botanix Pharmaceuticals trades on the ASX under the ticker symbol "BOT."

How much money does Botanix Pharmaceuticals make?

Botanix Pharmaceuticals has a market capitalization of $0.00 and generates $6.89 million in revenue each year.

How many employees does Botanix Pharmaceuticals have?

Botanix Pharmaceuticals employs 1 workers across the globe.

What is Botanix Pharmaceuticals' official website?

The official website for Botanix Pharmaceuticals is www.botanixpharma.com.

Where are Botanix Pharmaceuticals' headquarters?

Botanix Pharmaceuticals is headquartered at Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia.

How can I contact Botanix Pharmaceuticals?

Botanix Pharmaceuticals' mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580.


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.